%0 Journal Article %A Giordano, Federica %A Vaira, Valentina %A Cortinovis, Diego %A Bonomo, Sara %A Goedmakers, Joyce %A Brena, Federica %A Cialdella, Annamaria %A Ianzano, Leonarda %A Forno, Irene %A Cerrito, Maria %A Giovannoni, Roberto %A Ferri, Gian %A Tasciotti, Ennio %A Vicent, Silve %A Damarco, Francesco %A Bosari, Silvano %A Lavitrano, Marialuisa %A Grassilli, Emanuela %D 2019 %T Additional file 4: of p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma %U https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_p65BTK_is_a_novel_potential_actionable_target_in_KRAS-mutated_EGFR-wild_type_lung_adenocarcinoma/8280347 %R 10.6084/m9.figshare.8280347.v1 %2 https://springernature.figshare.com/ndownloader/files/15481520 %K NSCLC %K Drug resistance %K p65BTK %K BTK inhibitors %K EGFR %K EGFR inhibitors %K Targeted therapy %K Chemotherapy %X Figure S3. p65BTK expression in T cells. FACS-purified CD3 cell lysate was tested for p65BTK expression by BN49 antibody and for p77BTK expression using the anti-BTK (#611117, from Becton Dickinson. 100 pg of purified p77BTK (#B4312, Sigma-Aldrich) were also loaded as a positive control. (PDF 469 kb) %I figshare